Clinical activity after fingolimod cessation: disease reactivation or rebound?

European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies
J Fraui-MuST study group

Abstract

There is debate as to whether the apparent rebound after fingolimod discontinuation is related to the discontinuation itself or whether it is due to the natural course of highly active multiple sclerosis (MS). Our aim was to survey the prevalence of severe reactivation and rebound after discontinuation of fingolimod in a cohort of Italian patients with MS. Patients with relapsing-remitting MS who were treated with fingolimod for at least 6 months and who stopped treatment for reasons that were unrelated to inefficacy were included in the analysis. A total of 100 patients who had discontinued fingolimod were included in the study. Fourteen patients (14%) had a relapse within 3 months after fingolimod discontinuation, and an additional 12 (12%) had a relapse within 6 months. According to this study's criteria, 10 patients (10%) had a severe reactivation. Amongst these patients, five (5%) had a reactivation that was considered to be a rebound. The present study showed that more than 26% of patients are at risk of having a relapse within 6 months after fingolimod discontinuation. Nevertheless, the risk of severe reactivations and rebound is lower than has been previously described.

References

Jan 22, 2010·The New England Journal of Medicine·Ludwig KapposUNKNOWN FREEDOMS Study Group
Feb 15, 2012·Archives of Neurology·Joachim B HavlaTania Kümpfel
Jul 26, 2012·Multiple Sclerosis : Clinical and Laboratory Research·Bahia HakikiMaria Pia Amato
Apr 24, 2014·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Loredana La MantiaAlessandra Protti
Jul 1, 2013·Multiple Sclerosis and Related Disorders·Roy G BeranDennis J Cordato
Nov 12, 2015·Therapeutic Advances in Neurological Disorders·Simon FaissnerGisa Ellrichmann
May 3, 2016·JAMA Neurology·Stacy Ellen HatcherJennifer S Graves
Jan 21, 2017·Multiple Sclerosis and Related Disorders·Tuncay GündüzMefkure Eraksoy
Feb 18, 2017·Neurologia i neurochirurgia polska·Anna CzłonkowskaTomasz Litwin
May 5, 2017·International Journal of Molecular Sciences·Marinella ClericoLuca Durelli
Jun 24, 2017·Multiple Sclerosis and Related Disorders·Benedetta ForciAnna Repice
Aug 15, 2017·Neurology. Neuroimmunology and Neuroinflammation·Giovanni NoviAntonio Uccelli
Oct 11, 2017·Multiple Sclerosis Journal - Experimental, Translational and Clinical·Patrick VermerschMark S Freedman

❮ Previous
Next ❯

Citations

Jul 1, 2018·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·A Członkowska, D Mirowska-Guzel
Jul 26, 2019·Rinshō shinkeigaku = Clinical neurology·Ritsu AkataniRiki Matsumoto
Jun 4, 2019·Clinical Drug Investigation·Yara D FragosoHeloisa H Ruocco
Nov 5, 2019·Neurology and Therapy·Brian BarryCarlo Tornatore
Jun 14, 2019·Journal of Neurology, Neurosurgery, and Psychiatry·Damiano BaronciniMauro Zaffaroni
May 16, 2019·Neurology. Neuroimmunology and Neuroinflammation·Caterina LapucciLuca Roccatagliata
Apr 11, 2020·Neurology. Neuroimmunology and Neuroinflammation·Erik EllwardtStefan Bittner
Jul 14, 2020·Therapeutic Advances in Neurological Disorders·Kristen M KryskoKerstin Hellwig
Mar 14, 2019·Journal of Neurology·Jessica FrauEleonora Cocco
Oct 4, 2020·Journal of the Neurological Sciences·Maria CellerinoGiacomo Boffa
Apr 16, 2021·Multiple Sclerosis : Clinical and Laboratory Research·Elisabetta SignorielloAlessio Signori
Apr 11, 2021·Multiple Sclerosis and Related Disorders·Vasiliki PantazouMarie Théaudin
May 20, 2021·Drug Design, Development and Therapy·Marzia FronzaEleonora Cocco
May 19, 2021·Multiple Sclerosis and Related Disorders·Marine Boudot de la MotteElisabeth Maillart
Jun 18, 2021·Journal of Neurology·Doriana LandiJessica Frau
Jun 24, 2021·Multiple Sclerosis and Related Disorders·Kévin BigautUNKNOWN French Group for Recommendations in Multiple Sclerosis (France4MS) and the Société Française de la Sclérose En Plaques (SFSE
Sep 9, 2021·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Assunta BiancoMassimiliano Mirabella

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.